Physician profile
Matthew Vargas
NPI 1790123115
$682.32
in general payments reported to CMS, 2019-2025
12 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $337 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $190.11 | 2024-2025 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.95 | 2025 | Caplyta |
| Lilly USA, LLC | $117.51 | 2024 | Mounjaro |
| Amgen INC. | $47.18 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $43.36 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $37.88 | 2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.21 | 2025 | Xifaxan |
| Astellas Pharma US INC | $22.81 | 2025 | Veozah |
| Abbott Laboratories | $21.63 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $16.90 | 2024 | |
| Dexcom, INC. | $14.70 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $14.08 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.